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Impulse control disorders (ICDs), including disordered gambling, can occur in a significant
number of patients with Parkinson’s disease (PD) receiving dopaminergic therapy.The neu-
robiology underlying susceptibility to such problems is unclear, but risk likely results from an
interaction between dopaminergic medication and a pre-existing trait vulnerability. Impulse
control and addictive disorders form part of a broader psychopathological spectrum of dis-
orders, which share a common underlying genetic vulnerability, referred to as externalizing.
The broad externalizing risk factor is a continuously varying trait reflecting vulnerability to
various impulse control problems, manifested at the overt level by disinhibitory symptoms
and at the personality level by antecedent traits such as impulsivity and novelty/sensation
seeking.Trait “disinhibition” is thus a core endophenotype of ICDs, and a key target for neu-
robiological investigation. The ventral striatal dopamine system has been hypothesized to
underlie individual variation in behavioral disinhibition. Here, we examined whether individ-
ual differences in ventral striatal dopamine synthesis capacity predicted individual variation
in disinhibitory temperament traits in individuals with PD. Eighteen early-stage male PD
patients underwent 6-[18F]Fluoro-l-DOPA (FDOPA) positron emission tomography scanning
to measure striatal dopamine synthesis capacity, and completed a measure of disinhibited
personality. Consistent with our predictions, we found that levels of ventral, but not dor-
sal, striatal dopamine synthesis capacity predicted disinhibited personality, particularly a
propensity for financial extravagance. Our results are consistent with recent preclinical
models of vulnerability to behavioral disinhibition and addiction proneness, and provide
novel insights into the neurobiology of potential vulnerability to impulse control problems
in PD and other disorders.
Keywords: dopa decarboxylase, dopamine, disordered gambling, externalizing, impulse control disorders, impul-
sivity, reward, ventral striatum
INTRODUCTION
Several addictive and impulse control disorders (ICDs) have been
associated with Parkinson’s disease (PD) and its treatment with
dopaminergic medication, including disordered gambling (Gal-
lagher et al., 2007), substance dependence (Bienfait et al., 2010),
and the addiction-like excessive use of dopaminergic medica-
tions, or DA dysregulation syndrome (Lawrence et al., 2003).
The prevalence of ICDs in medicated PD patients was estimated
at ∼14% in a large (n> 3000) multicentre study, with >25%
of affected individuals having multiple ICDs (Weintraub et al.,
2010). The development of ICDs in PD likely results from an
interaction between dopaminergic medication and an underly-
ing vulnerability, rather than from PD itself, since: (a) only a
(substantial) minority of medicated PD patients develop ICDs
(Weintraub et al., 2010); (b) ICDs are no more frequent in
patients with de novo PD than in the general population (Wein-
traub et al., 2013); (c) ICDs can develop in non-PD individ-
uals treated with dopaminergic medication (O’Sullivan et al.,
2010; Voon et al., 2011a); and (d) a family history of gambling
problems is a risk factor for the development of dopaminergic
medication-linked ICDs (Weintraub et al., 2010; Voon et al.,
2011a).
This precursive ICD vulnerability likely reflects variation in pre-
existing temperament/personality (Dagher and Robbins, 2009),
in particular, variation in the broad temperament dimension of
trait disinhibition (vs. constraint), encompassing impulsivity, nov-
elty/sensation seeking, non-planning, low self-control, and related
constructs (Markon et al., 2005). In PD, just as in non-PD popula-
tions (Sher and Trull, 1994; MacLaren et al., 2011), phenotypic
associations between trait disinhibition and substance use and
ICDs (and their comorbidity) have been repeatedly demonstrated
(Evans et al., 2005; Voon et al., 2011b).
These findings suggest etiologic similarities between ICDs
and addictions in PD and the broader domain of externalizing
(EXT) psychopathology in non-PD populations (Krueger et al.,
2007). Patterns of phenotypic, environmental, and genetic rela-
tions among DSM-defined substance misuse and antisocial disor-
ders are best accounted for by models positing a shared broad EXT
factor or vulnerability (Krueger et al., 2007). I.e., putatively dis-
tinct disorders are better understood as variants within a broader
www.frontiersin.org February 2013 | Volume 4 | Article 90 | 1
Lawrence et al. Financial extravagance in Parkinson’s disease
EXT spectrum of disorders, and the reason they systematically
co-occur is because they share a common underlying genetic vul-
nerability (Krueger et al., 2007). This broad EXT vulnerability
is a continuously distributed dimension of risk (Krueger et al.,
2007). Hierarchical models of the EXT spectrum (Krueger et al.,
2007) posit a general factor linking all EXT syndromes, as well as
distinct etiological factors that differentiate among distinct EXT
syndromes. Disordered gambling, frequently comorbid with sub-
stance abuse and antisocial personality disorder (Kessler et al.,
2008) is also considered one variant of EXT (Oleski et al., 2011;
Blanco et al., 2012; Forbush and Watson, 2013; but see Slutske
et al., 2013).
A shared genetic diathesis underlies the phenotypic associa-
tions between EXT disorders and disinhibited personality traits,
including novelty seeking (NS; Young et al., 2000; Agrawal et al.,
2004). Furthermore, prospective studies suggest that high levels
of these traits in childhood and adolescence predate and predict
the emergence of EXT psychopathology in adulthood (Sher et al.,
2000; Slutske et al., 2012). I.e., the temperamental antecedent of
disinhibition provides the core endophenotype of EXT disorders
(Clark, 2005),mediating their systematic co-variation (Khan et al.,
2005). Hence, understanding the genetics and neurobiology of
disinhibitory personality traits is critical to understanding EXT
psychopathology, including its manifestation in the context of PD
and its treatment with DA replacement therapies.
The DA system has frequently been hypothesized to underlie
individual variation in trait disinhibition.According to one promi-
nent model (Pickering and Gray, 1999), individual differences
along this temperament dimension are argued to reflect variation
in the reactivity of a neural behavioral activation system (BAS),
centered on the ventral striatum (VS), and its dopaminergic irriga-
tion,activatedby cues for reward. Similarly, according toCloninger
(1987), the disinhibitory temperament trait of NS reflects genet-
ically determined variation in dopaminergically mediated BAS
reactivity. When activated, the BAS can be characterized as an
impulsive “go” system that activates on-going appetitive behavior
(Pine et al., 2010).
Research is accumulating to suggest that variation in the DA
synthesis pathway in particular plays a key role in the etiology
of EXT. DA synthesis occurs within DA neurons. Tyrosine is
transported into the cell via amino acid carriers in the blood-
brain barrier and cell membranes. Once in the intracellular space
it is hydroxylated to l-3,4-dihydroxiphenylalanine (l-DOPA) by
tyrosine hydroxylase (TH). l-DOPA is thendecarboxylated by aro-
matic l-amino acid decarboxylase [AADC; also known as dopa
decarboxylase (DDC)] to DA (Elsworth and Roth, 2009). Vari-
ants [single nucleotide polymorphisms (SNPs)] in the DDC gene
have been associated with nicotine (Ma et al., 2005; Yu et al., 2006;
Zhang et al., 2006), alcohol (Agrawal et al., 2011; Kristjansson
et al., 2012) and illicit drug (Hack et al., 2011) misuse, and most
recently,disordered gambling (Lind et al., 2012). Importantly,Der-
ringer et al. (2010) found that a combination of multiple SNPs in
the DDC gene predicted individual variation in sensation seeking
traits, suggesting that genetic variation in DA synthesis is related
to broad EXT risk.
Positron Emission Tomography (PET) can be used to study
the activity of AADC/DDC in pre-synaptic DA terminals in the
living brain. The PET tracer 6-[18F]fluoro-l-DOPA (FDOPA),
a radioactive analog of l-DOPA, the precursor of DA, is taken
up by pre-synaptic dopaminergic neurons and is metabolized
by AADC/DDC to 18F-DA, which is trapped and stored within
vesicles in the nerve terminals (Kumakura and Cumming, 2009).
FDOPA uptake, quantified as the influx constant K I, can be used
as a measure of AADC/DDC activity and vesicular storage capac-
ity (Brown et al., 1999). High values for FDOPA K I are observed
in areas of dense DA nerve terminal innervation, such as the stria-
tum, and FDOPAhas been extensively used to probe the functional
integrity of striatal dopaminergic neurons in PD (Brooks, 2010)
where uptake correlates with the number of surviving nigrostri-
atal cell numbers (Snow et al., 1993). Notably, FDOPA studies in
non-PD populations have shown relatively increased striatal K I
values in alcohol (Tiihonen et al., 1998) and nicotine (Salokangas
et al., 2000) dependent individuals, although those early studies
did not measure disinhibitory personality traits, and could not
resolve dorsal and ventral striatal regions. Further, Laakso et al.
(2005) found increased striatal FDOPA uptake in A1+ allele car-
riers of the Taq1A polymorphism of the TTC12-ANKK1-DRD2
gene cluster, variation in which has been linked with EXT risk
(Ducci et al., 2011).
Collectively, the research outlined above suggests that individ-
ual variation in DA synthesis capacity, particularly in the VS,
underpins individual variation in trait disinhibition. Here, we
tested the hypothesis that increased FDOPA uptake inVS,which is
relatively spared in PD (Kish et al., 1988), would predict increased
trait disinhibition or general EXT risk, in the context of PD.
MATERIALS AND METHODS
PATIENTS
We studied 18men with early-stage (symptom duration<2 years)
idiopathic PD based on UK PD Society Brain Bank diagnostic
criteria. Table 1 summarizes their clinical characteristics. Disease
severity was rated with the Unified Parkinson’s Disease Rating
Scale (UPDRS) motor subscale while in an “off” condition with-
drawn from medication before PET. Assessment of trait disinhi-
bition, as well as PET scanning, was performed in a practically
defined off state. Patients with pronounced tremor that would
have produced difficulty with PET imaging, as well as patients with
comorbid psychiatric or systemic physical illness were excluded.
This cohort of 18 patients was drawn from a larger group of 186
PD patients that formed the multicentre REAL-PET investigation
enrolled population. Drug escalation, tablet frequency, dose, and
UPDRSmotor response to medication have been described previ-
ously (Whone et al., 2003b). At the time of PET scanning, patients
had only been started on dopaminergic medication within the
Table 1 | Patient characteristics.
Parkinson’s disease
patients (n= 18)
0/81)elamef/elam(redneG
Age (years, mean±SD, range) 64± 7, range 47–76
UPDRS motor in “off” (mean±SD) 14.6± 6.5
GDS Depression (mean±SD) 9.8± 8.9
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previous 4–12 weeks, and were receiving low doses of either l-
DOPA (between 300 mg to a maximum daily dose of ∼400 mg
at time of PET) or a DA agonist (between 3 mg of ropinirole
to a maximum daily dose of ∼8 mg at time of PET). Patients
were administered the 30-item Geriatric Depression Scale (GDS),
validated for use in PD (Ertan et al., 2005).
The study was limited to men for several reasons. Firstly, ICDs
and addictions in PD are more prevalent in males than females
(Weintraub et al., 2010), as they are in non-PD populations (Eaton
et al., 2012). Secondly, there are sex differences in DA synthesis
capacity (Laakso et al., 2002). Thirdly, genetic factors for NS are
excellent markers for EXT tendencies in males, but not females
(Agrawal et al., 2004; Pitzer et al., 2007), although it is unclear
whether this sex difference is an artifact of the manner in which
males and females interpret the NS construct or whether there
are true differences in the magnitude of genetic influence across
males and females. It will be important in future studies to include
females with PD.
Permission to undertake the study was granted by the Ethics
Committee of Hammersmith, Queen Charlotte’s & Chelsea, and
Acton Hospital Trust and all participants gave written informed
consent following a full explanation of the procedure, in accor-
dance with the declaration of Helsinki. The Administration of
Radioactive Substances Advisory Committee (ARSAC) of the UK
approved radioisotope use.
MEASUREMENT OF TRAIT DISINHIBITION (VS. CONSTRAINT)
Our measure of trait disinhibition (vs. constraint) was based
on NS from Cloninger’s Tri-dimensional Personality Question-
naire (TPQ; Cloninger, 1987). The version of the TPQ used
here was a 100-item, self-administered, true-false instrument. The
questionnaire is scored so that higher scores reflect greater NS.
As originally constructed (Cloninger, 1987) TPQ-NS com-
prised four narrow facet-level scales: Exploratory Excitability vs.
Stoic Rigidity (NS1), Impulsiveness vs. Reflection (NS2), Extrav-
agance vs. Reserve (NS3), and Disorderliness vs. Regimentation
(NS4). When Ando et al. (2004), however, examined the genetic
and environmental factor structure of NS, factor analysis of the
genetic inter-correlations yielded factors that did not fully resem-
ble the phenotypic structure of NS as proposed by Cloninger
(1987). NS was revised (r-NS) to consist of Impulsiveness vs.
Reflection (NS2), Extravagance vs. Reserve (NS3) and Disorderli-
ness vs. Regimentation (NS4), excluding Exploratory Excitability
vs. Stoic Rigidity (NS1). Further, Flory et al. (2006), using fac-
tor analysis in a large normative sample of middle-aged adults,
found Impulsiveness vs. Reflection (NS2) and Extravagance vs.
Reserve (NS3) to have high loadings on a “non-planning impul-
sivity” factor, together with the Barratt Impulsiveness Scale (BIS),
whereas Exploratory Excitability vs. Stoic Rigidity (NS1) loaded on
a distinct “Openness to Experience” factor, and Disorderliness vs.
Regimentation (NS4) failed to load strongly on any single factor.
Hence, in the current study, we focused on those r-NS facets most
strongly linked to trait disinhibition: Impulsiveness (vs. Reflec-
tion; NS2; eight items) and Extravagance (vs. Reserve; NS3; seven
items). Sample items include “I often react so strongly to unexpected
news that I say or do things that I regret,” “I often have to change my
decisions because I had a wrong hunch or mistaken first impression”
(Impulsivity, NS2) and “I often spend money until I run out of cash
or get into debt from using too much credit,”“Because I so often spend
too much money on impulse, it is hard for me to save money – even
for special plans like a vacation” (Extravagance, NS3).
PET SCANNING PROTOCOL
Patients stopped medication at least 12 h prior to scanning. All
participants underwent three-dimensional FDOPA PET using an
ECAT EXACT HR++ (CTI/Siemens 966) camera, which covers
an axial field of view of 23.4 cm and provides 95 transaxial planes.
The tomograph has a spatial resolution of 4.8+ 0.2 mm FWHM
(transaxial, 1 cm off axis) and 5.6+ 0.5 mm (axial, on axis) after
image reconstruction (Spinks et al., 2000). A transmission scan,
which corrects for attenuation of emitted radiation by skull and
tissues, was acquired using a single rotating photon point source
of 150 MBq of 137Cs. Thirty seconds after the start of the emis-
sion scan, 110 MBq of FDOPA in 10 ml normal saline was infused
intravenously over 30 s. Three-dimensional sinograms of emission
data were then acquired over 94 min as 26 time frames. Patients
were placed in the scanner, orientated parallel to the orbito-metal
line and head positioning was monitored throughout the scan.
IMAGE QUANTIFICATION
Parametric images of specific FDOPA uptake (KI maps) were cre-
ated at a voxel level for the whole brain using the Patlak graphical
approach (Patlak and Blasberg, 1985) with a cerebellar cortex ref-
erence input function (Moore et al., 2003). Qualitative summated
images created from the dynamic FDOPA time series by inte-
grating all 26 frames of the dynamic image were also produced
and then transformed into standard stereotaxic [Montreal Neuro-
logical Institute (MNI)] space using an FDOPA template created
in-house from a healthy volunteer database. These so-called ADD
images contain both tracer delivery and specific uptake informa-
tion and provide adequate anatomical detail to allow stereotaxic
manipulations. Subsequently, the KI maps were also individually
normalized to MNI stereotaxic space by applying the transfor-
mation parameters defined during the normalization of their
respective ADD image. This spatial transformation of paramet-
ric images made it possible to perform a region of interest (ROI)
analysis as described below.
REGION OF INTEREST ANALYSIS
An ROI analysis was performed using a fixed object map tem-
plate after stereotaxic transformation of all images into standard
(MNI) space. This approach effectively normalizes brain position
and shape and so avoids variability of regions due to head size
and position and subjective free hand definition. Standard ROI
object maps that outlined the left and right hemisphere VS, cau-
date, and putamen were defined on the MNI single-subject ROI in
stereotaxic space (Moore et al., 2003, 2008). The standard object
map was placed onto the transformed KI maps, and values for spe-
cific FDOPA uptake were obtained for each region (see Figure 1
for ROIs). When performing our ROI analysis a manual correc-
tion for head movement was employed as described previously
(Whone et al., 2003a).
To limit the number of comparisons, and because of our spe-
cific a priori hypothesis, K I values (units: ml g−1 min−1) for the
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FIGURE 1 |The figure shows in (A) an FDOPAADD (summed) and
net influx rate constant (K I) image of a single slice from a healthy
individual (top panels) and a patient with PD (bottom panels). In
these images normalization to (MNI) space has been performed.
Asymmetric decreased putamen and caudate uptake can be seen in
the patient with PD. In (B) the figure shows; a template region object
map overlying: the putamen and caudate nucleus bilaterally in a
normalized FDOPA ADD image from a PD patient; the FDOPA template
(created from five healthy controls) and the canonical single-subject T1
MRI found in SPM 99. (C) Shows the template object map, with
volumes shaded, for the ventral striatum and caudate nucleus overlain
on the canonical single-subject T1 MRI in sagittal section and next to it
a spatially normalized KI image in sagittal section with the ventral
striatum and caudate nucleus object map overlain. Also shown is a
spatially normalized coronal section KI map through the ventral striatum
with the object map overlain.
caudate and putamen ROIs were averaged to form left and right
dorsal striatum (DS) ROIs. Exploratory data analysis revealed that
K I and NS data were normally distributed, and so we examined
the relation between them using Pearson’s correlation coefficient.
Statistical significance was set at p< 0.01.
RESULTS
Mean± SD scores in our PD sample for NS2 (Impulsivity) and
NS3 (Extravagance) were 3.1± 1.6 and 3.1± 1.7, respectively.
Whilst population norms for individual NS facets are unavail-
able, the total NS score (NS1+NS2+NS3+NS4) of the current
PD sample (13.6± 4) was comparable to that published for age-
matched healthy male controls (n> 1000; mean age 67± 8; total
NS= 11.6± 5; Stallings et al., 1996). Mean± SD FDOPA K I val-
ues for left and right VS and left and right DS are reported in
Table 2.
In line with our a priori hypothesis, we found a significant cor-
relation betweenNS3 (Extravagance) scores and leftVS FDOPAK I
values [r (16)= 0.61,p= 0.008,95%CI 0.20 – 0.83;Figure 2]. This
relationship was unchanged when controlling for both age and
GDS depression scores (r = 0.63, p= 0.009). There was a similar
Table 2 | FDOPA K I values in regions of interest.
APODFnoigeR K I values
(mean±SD)
7210.0mutairtslartnevtfeL ± 0.0015
0210.0mutairtslartnevthgiR ± 0.0014
5110.0mutairtslasrodtfeL ± 0.0018
8010.0mutairtslasrodthgiR ± 0.0015
trend in the right VS that failed to reach our pre-specified level of
statistical significance (r = 0.53, p= 0.026). (An additional analy-
sis revealed that the slightly greater correlation between left VS
FDOPA K I and NS3 was not a result of asymmetry of Parkinson-
ian symptoms). Furthermore, neither left (r =−0.13, p= 0.60)
nor right (r =−0.22, p= 0.38) VS FDOPA K I values correlated
with UPDRS motor scores. There was no significant relation
between DS FDOPA K I values and NS3 scores, although the cor-
relation with right DS values trended toward significance (left,
r = 0.27,p= 0.27; right, r = 0.41,p= 0.09). Importantly, however,
the correlation between left VS FDOPA K I values and NS3 scores
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FIGURE 2 | Scatter plot (and line of best fit) showing the relation
between trait disinhibition (NS3, Extravagance vs. reserve) and ventral
striatal dopamine synthesis capacity (FDOPA K I) in Parkinson’s
disease.
was significantly greater than that between either left [t = 2.59, p
(1-tail)= 0.01] or right [t = 1.46, p (1-tail)= 0.08] DS FDOPA K I
values and NS3 scores.
Against our hypothesis, however, there was no significant cor-
relation between NS2 (Impulsivity) scores and VS FDOPA K I
values (left, r = 0.08, p= 0.77; right, r = 0.30, p= 0.22). Nor was
there a significant correlation between NS2 scores and DS K I
values (left, r =−0.12, p= 0.65; right, r = 0.22, p= 0.37). The
correlation between left VS FDOPA K I values and NS3 (Extrav-
agance) scores was significantly greater than that between left
VS FDOPA K I values and NS2 (Impulsivity) scores [t = 2.67, p
(1-tail)= 0.008].
DISCUSSION
Our findings provide new insights into the neurobiology of poten-
tial vulnerability to impulse control problems in PD. Consistent
with our hypothesis, we found that variation in trait disinhibition
(vs. constraint), a continuously varying endophenotype for EXT
or impulse-control psychopathology, was associated with levels of
DA synthesis capacity in the VS. Individuals with higher levels of
trait disinhibition, in particular, tendencies to financial irrespon-
sibility and extravagance, had greater DA synthesis capacity, as
indexed by FDOPA K I values in the left (and to a lesser extent,
right) ventral, but not dorsal, striatum.
Although ICDs in PD have to date been treated as categori-
cal (present/absent) disorders, it is now widely accepted that such
disorders do not delineate highly discrete and easily distinguished
categories. Rather, they delineate continuous, normally distrib-
uted underlying propensities to experience psychopathology, with
personality traits linked to behavioral disinhibition forming the
core of an EXT spectrum (Clark, 2005; Krueger et al., 2007). I.e.,
psychopathology represents the extremes of continuously distrib-
uted temperament traits. This general temperamental propensity
to EXT, rather than its manifestations in particular disorders is
therefore a key focus for etiological investigations.
Whilst a recent study linked genetic variation in DDC activity
to an EXT endophenotype (sensation seeking) in healthy individ-
uals (Derringer et al., 2010), and sensation seeking has been linked
to increased ventral striatal BOLD-fMRI response during reward
anticipation (Bjork et al., 2008; see also Yau et al., 2012), ours
is the first demonstration that variation in trait disinhibition is
linked to variation in DDC activity in the VS in PD, an important
brain region underlying inter-individual variation in behavioral
disinhibition in preclinical models (Dalley et al., 2011).
We found that only the r-NS subscale NS3 (Extravagance vs.
Reserve) was related to ventral striatal DA synthesis capacity. There
was no such relation with the NS2 subscale (Impulsivity vs. Reflec-
tion), despite the relatively high correlation between NS2 and NS3
(r = 0.45). Both subscales showed a similar range of variation in
our PD sample, suggesting this is not the reason for a lack of
correlation between NS2 scores and VS FDOPA K I values. NS3
appears more trait-like (evidenced by much higher test-rest corre-
lation) than NS2 (Takeuchi et al., 2011), and appears to index those
traits (irresponsibility, inability to approach life planfully) most
strongly linked to general EXT risk (Krueger and South, 2009).
It is particularly notable that only NS3 correlates with impaired
decision-making on the Iowa Gambling Task (Álvarez-Moya et al.,
2011), which has been linked to increased VS FDOPA K I values
(Schlagenhauf et al., 2012).
On first glance, our results appear inconsistent with an earlier
study that failed to find a correlation between trait NS and VS
FDOPA K I values in unmedicated male PD patients (Kaasinen
et al., 2001). However, that study used the total NS score from the
original NS scales described by Cloninger (1987), and it is now
clear (Ando et al., 2004) that the genetic and environmental factor
structure of NS does not resemble the phenotypic structure of NS
as originally proposed, making interpretation of that previous null
result difficult.
FDOPA is not a specific ligand for DA neurons but rather is
trapped by all neurons that contain DDC (Brown et al., 1999).
Hence, it is a marker for all tissues that take up and store
monoamines, including serotonin (5-HT) as well as DA neu-
rons (Tison et al., 1991). 5-HT has also been implicated in var-
ious aspects of impulsivity (Winstanley et al., 2005; Miyazaki
et al., 2011). However, post hoc analysis of a midbrain raphe
ROI (Moore et al., 2008), a structure in which FDOPA is a
validated marker of serotonergic function in PD (Pavese et al.,
2012), in our sample, found no significant correlation between
FDOPA K I values in the raphe and either NS2 (Impulsivity)
or NS3 (Extravagance) scores (r = 0.11, p= 0.67 and r = 0.32,
p= 0.2, respectively). Further, in MPTP treated monkeys, Karimi
et al. (2013) found a near perfect correlation (n= 16, r2= 0.95)
between striatal FDOPA K I values obtained in vivo with PET
and post-mortem striatal DA levels (measured using high perfor-
mance liquid chromatography with electrochemical detection). It
is likely, therefore, that individual differences in trait disinhibi-
tion are primarily related to individual differences in DA synthesis
capacity.
This interpretation is consistent with several other recent
findings on the neurobiology of impulse-control and addiction
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vulnerability. D2 autoreceptors located on DA nerve terminals
exert a negative feedback regulation that reduces DA synthe-
sis, DA neuron firing, and DA release (Wolf and Roth, 1990;
Zhu et al., 1992). Bello et al. (2011) generated mice defi-
cient in such D2 autoreceptors. These “autoDrd2KO” mice dis-
played elevated striatal DA synthesis and strikingly, demon-
strated increased sensitivity to the rewarding and psychomo-
tor stimulant properties of cocaine, together with a greatly
exaggerated motivation to work for food reward. I.e., height-
ened DA synthesis in the autoDrd2KO mice resulted in an
addiction-prone, disinhibited phenotype. In humans, striatal DA
synthesis capacity measured with [β-11C]DOPA PET is nega-
tively correlated with striatal D2 receptor density measured with
[11C]raclopride PET (Ito et al., 2011). Given that many pre-
synapticD2 receptors in the striatumareDAautoreceptors (Sesack
et al., 1994), increased DA synthesis capacity in humans may
similarly reflect reduced D2 autoreceptor function. Notably, in
animal models, variation in trait impulsivity, measured by pre-
mature responding on a 5-choice serial reaction time test of
visual attention, has been linked to relatively reduced D2 recep-
tor levels in the VS, functioning as autoreceptors (Besson et al.,
2010).
Consistent with this, in humans, Buckholtz et al. (2010) (see
also Zald et al., 2008) recently found that trait non-planning
impulsivity was inversely correlated with D2/D3 autoreceptor
availability in the substantia nigra/ventral tegmental area, mea-
sured using [18F]fallypride PET. Furthermore, Van Leare et al.
(2009) found a selective negative correlation between cannabi-
noid CB1 receptor density, measured using [18F]MK-9470 PET,
in left hemisphere limbic regions and NS3 (Extravagance) scores
in healthy volunteers. Since CB1 receptor activation causes inhi-
bition of DA synthesis (Moranta et al., 2004), reduced density
of CB1 receptors would presumably result in higher levels of
DA synthesis, and the negative correlation between CB1 recep-
tor density and NS3 is consistent with the positive correlation
between ventral striatal DA synthesis capacity and NS3 seen
here.
Furthermore, Bello et al. (2011) found that autoDrd2KO
mice showed exaggerated phasic DA release, resulting from a
larger releasable pool of DA generated by the lack of DA syn-
thesis inhibition in DA terminals. Similarly, in both monkeys
(Doudet and Holden, 2003) and human individuals with PD
(Piccini et al., 2003), the magnitude of amphetamine-induced
striatal DA release as measured by [11C]-raclopride PET (an
indirect measure of phasic DA release, Grace, 2008), is pos-
itively correlated with DA synthesis capacity measured using
FDOPA PET. In humans, Buckholtz et al. (2010) found that
trait disinhibition predicted greater amph-induced DA release
(together with stronger drug-primed wanting) and the relation
between midbrain autoreceptor availability and trait impulsivity
wasmediated via this enhanced amphetamine-induced striatal DA
release.
The influence of variation inDA synthesis capacity on EXT ten-
dencymight result fromDA’s established role in reward processing,
particularly the attribution of incentive salience (Berridge, 2007).
Incentive salience is amotivational component of reward, one that
transforms sensory information about rewards and reward cues
into attractive, “wanted” incentives, motivating pursuit (Berridge,
2007). Notably, in animals, there is considerable individual vari-
ability in incentive salience attribution, and rats with a strong
propensity to attribute incentive salience to reward cues also show
heightened behavioral disinhibition, risk-taking, and an increased
tendency to seek drugs like cocaine (Flagel et al., 2010). Available
data suggest that animals prone to attribute incentive salience to
reward cues have a more active DA system than those who do not
(Marinelli andWhite, 2000; Tomie et al., 2000). In healthy volun-
teers VS FDopa K I values have been found to positively correlate
with BOLD-fMRI activity to reward cues in brain regions linked
to incentive salience attribution (Siessmeier et al., 2006), and ven-
tral striatal BOLD-fMRI response to reward cues in humans is
increased as a function of trait non-planning impulsivity and is
linked to genetic variation in the D2 (auto)-receptor (Forbes et al.,
2009).
Of particular relevance to the development of extreme impulse
control problems following treatment with dopaminergic med-
ication in PD, rats with heightened incentive salience attribu-
tion show a greater propensity for dopaminergic drug-induced
sensitization – a form of neuroplasticity hypothesized to play
a key role in addiction (Flagel et al., 2008). In particular, the
incentive-sensitization theory (Robinson and Berridge, 2008)
posits that excessive drug use arises from the excessive attri-
bution of incentive salience to drug rewards and their cues,
due to progressive neuroadaptations in DA projections to ven-
tral striatal motivation circuitry. Strikingly, PD individuals with
DA dysregulation syndrome were shown to exhibit potenti-
ated l-DOPA-induced ventral striatal DA release, which corre-
lated with exaggerated drug-primed l-DOPA wanting, together
with enhanced responding to monetary reward (Evans et al.,
2006). Also, PD (and non-PD) individuals with disordered
gambling showed impaired DA D2 autoreceptor activity (Ray
et al., 2012) and exaggerated VS DA release to gambling and
other reward cues (O’Sullivan et al., 2011; see also Steeves
et al., 2009; Joutsa et al., 2012a), consistent with incentive-
sensitization.
It is possible that, rather than reflecting an underlying neu-
robiological risk factor for ICDs in PD, increased VS FDOPA
uptake could be the result of disease-related and/or drug-induced
neuroplastic changes leading to disease- and/or drug-induced dis-
inhibition. In the current sample of early-stage PD patients, who
had only recently begun DA replacement therapy, however, mean
ventral striatal FDOPA K I values were very similar to those of
healthy controls (Whone et al., 2004) and were unrelated to sever-
ity of PD. In animal models, there is some evidence that repeated
treatments with DA agonist drugs can enhance basal DA synthe-
sis in the VS (Rowlett et al., 1997) and frontal cortex (Chernoloz
et al., 2012). However, other studies show persistent inhibition
of DA synthesis following repeated treatment with DA agonists
(Imperato et al., 1996). A study of detoxified alcoholics found no
differences in VS DA synthesis capacity measured with FDOPA
PET (Heinz et al., 2005). Very recently, Joutsa et al. (2012b)
found increased medial orbitofrontal, but not ventral striatal,
FDOPA uptake in 10 individuals with manifest ICDs in PD. Since
disinhibitory traits were not measured in the patients or controls
of that study, however, it may be that several of the controls had
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high EXT risk, explaining the lack of difference in VS FDOPA
uptake between ICD cases and controls. Frontal, but not striatal,
DA synthesis is also increased following stress (Reinhard et al.,
1982), suggesting that enhanced frontal, but not ventral striatal,
FDOPA uptake in ICD cases may reflect state, as opposed to trait,
effects.
Furthermore, Giladi et al. (2007) and Bastiaens et al. (2013)
found that the appearance of heightened impulse control prob-
lems in affected PD individuals began only after a median interval
of ∼2 years of treatment, and our patients had only recently
been started on dopaminergic medication, within the previous
4–12 weeks, and were on only low doses of either l-DOPA or DA
agonist. In addition, Voon et al. (2007) found that NS scores were
not influenced by dopaminergic therapy. Importantly, numerous
studies have found a shared genetic diathesis to underlie associ-
ations between EXT disorders and traits related to disinhibition,
including NS (Young et al., 2000; Agrawal et al., 2004). Most criti-
cally, Derringer et al. (2010) found that genetic variation in DDC
activity predicted variation in trait disinhibition, suggesting that
variation in DDC activity reflects a trait EXT vulnerability, rather
than a disease or medication-related effect (see also Engeln et al.,
2012). Likewise, Flagel et al. (2010), found that, in rats, varia-
tion in incentive salience attribution and behavioral disinhibition
are genetically influenced, correlated traits that depend on ventral
striatal DA for their expression (Saunders and Robinson, 2012).
Hence, we think it highly unlikely that our findings of a posi-
tive correlation between levels of self-reported disinhibition and
VS DA synthesis capacity are a result of PD and its treatment with
dopaminergic medication. Rather, we think they reflect genetically
influenced, pre-existing neurobiological individual differences in
VS DA synthesis capacity in PD patients, underpinning variation
in trait disinhibition or EXT propensity, which in turn is associated
with future ICD morbidity risk (as PD advances and dopaminergic
drug therapy increases), resulting from an increased suscepti-
bility to DAergic-drug-induced incentive-sensitization (Boileau
et al., 2006). Longitudinal studies will be required to establish
the validity of this account.
In conclusion, we have shown that temperamental vulner-
ability to impulse control or EXT problems such as disor-
dered gambling in male PD patients is related to relatively
greater DA synthesis capacity in the ventral, but not dor-
sal, striatum. Our results are consistent with preclinical mod-
els of EXT risk, and may prove informative in understand-
ing the psychological and neurobiological mechanisms whereby
individual differences in temperament contribute to the devel-
opment of impulse control and addictive pathologies in the
context of the treatment of PD and other neurological disor-
ders.
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